HanAll Biopharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update 2024-11-01 19:00
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update 2024-07-26 19:00
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer 2024-07-15 19:00
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases 2024-05-28 19:00
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease 2024-05-03 19:00
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update 2024-04-30 19:00
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update 2024-03-21 19:00
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum 2023-12-20 20:00
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors 2023-12-11 20:00
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update 2023-10-26 19:00
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 2023-10-12 19:00
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update 2023-07-27 19:00
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease 2023-06-12 19:00
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease 2023-05-25 19:00
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease 2023-05-19 19:00
HanAll Biopharma Reports First Quarter Results and Provides Business Update 2023-04-28 19:00
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth 2023-03-29 19:00
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program 2023-03-15 19:00
HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis 2023-03-06 20:00
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities 2023-02-10 20:00
1 2